Revenue Decline
Revenue decreased by 0.4% year-over-year, indicating challenges in maintaining sales levels.
Source: 10-Q Income Statement
Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
TECH's Q2 FY2026 results show a slight decline in revenue but improved operating income and net income, highlighting effective cost management despite revenue pressures.
Revenue
$295.88M
-0.39% YoY
EPS (Diluted)
$0.24
+9.09% YoY
Gross Margin
64.6%
-0.6 pts YoY
Operating Income
$54.46M
+14.85% YoY
Source: SEC XBRL
BIO-TECHNE (TECH) reported Q2 FY2026 revenue of $295.88M, down 0.4% year over year. Operating margin was 18.4%, up 2.4 points from 16.0% a year earlier. TECH's fiscal Q2 FY2026 corresponds to calendar Q4 2025.
Last 4 quarters: 2 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Mar 2026 | 0.53 | 0.55 | Miss -3.3% |
| Dec 2025This filing | 0.46 | 0.44 | Beat +4.0% |
| Sep 2025 | 0.42 | 0.43 | Miss -2.0% |
| Jun 2025 | 0.53 | 0.51 | Beat +4.1% |
Adjusted (non-GAAP) EPS of $0.46 versus the $0.44 analyst consensus — a +4.0% beat for Dec 2025. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $0.24.
Compiled by AI from this SEC filing
Revenue decreased by 0.4% year-over-year, indicating challenges in maintaining sales levels.
Source: 10-Q Income Statement
Operating income increased by 14.9% due to reduced SG&A expenses, demonstrating effective cost control.
Source: 10-Q Income Statement
Operating margin improved to 18.4%, reflecting better operational efficiency.
Source: 10-Q Key Ratios
Compiled by AI from this SEC filing · 1 high, 2 medium, 0 low
The slight decline in revenue suggests potential challenges in market demand or competitive pressures, which could impact future growth.
Source: 10-Q Income Statement
Operating cash flow decreased by 25.8% year-over-year, which might affect liquidity if the trend continues.
Source: 10-Q Cash Flow
Total assets decreased by 5.5%, potentially impacting the company's ability to leverage its balance sheet for growth.
Source: 10-Q Balance Sheet
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $M | 295.88 $M | 297.03 $M | -0.39% |
Cost of Revenue $M | 104.60 $M | 103.15 $M | +1.41% |
Gross Profit $M | 191.28 $M | 193.89 $M | -1.35% |
Operating Income $M | 54.46 $M | 47.42 $M | +14.85% |
Net Income $M | 38.01 $M | 34.89 $M | +8.94% |
EPS (Basic) $ | 0.24 $ | 0.22 $ | +9.09% |
EPS (Diluted) $ | 0.24 $ | 0.22 $ | +9.09% |
SG&A Expense $M | 113.69 $M | 121.45 $M | -6.39% |
Answers draw on this SEC filing and the data on this page
Other companies in Life Sciences Tools & Services